Clinical and biochemical studies of high-dose thymidine treatment in patients with solid tumors

Albert Leyva, Jan H. Schornagel, Ineke Kraal, Sybe K. Wadman, Herbert M. Pinedo

Research output: Contribution to journalArticlepeer-review

Abstract

In a clinical study of high-dose thymidine (TdR) treatment, toxic effects, TdR metabolism, and the influence of TdR on pyrimidine and purine metabolism were examined. Ten patients with solid tumors were treated with continuous infusion of TdR at 34-75 g/m2/day for 3 to 5 days. Hematologic toxicity occurred with 5-day TdR infusion at 75 g/m2/day but not when plasma TdR concentration failed to reach millimolar levels. In three patients who received similar TdR doses, plasma TdR levels were related to elimination rates of TdR and its metabolites from plasma. In one patient in whom urinary excretion was studied, 100% of the TdR dose given was recovered in the form of TdR, thymine (Thy), β-aminoisobutyrate, and 5-hydroxymethyluracil (5-HMUra). The latter metabolite, which had not been previously described in high-dose TdR treatment, was also found in plasma at levels from 5% to 10% of those of TdR. No effects of high-dose TdR infusion on purine levels in plasma were observed, while a substantial increase in uracil levels was noted both in plasma and urine. These data provide further information on high-dose TdR treatment with regard to clinical, pharmacokinetic, and biochemical effects.

Original languageEnglish (US)
Pages (from-to)211-216
Number of pages6
JournalJournal of Cancer Research and Clinical Oncology
Volume107
Issue number3
DOIs
StatePublished - Oct 1984
Externally publishedYes

Keywords

  • Pyrimidines
  • Thymidine
  • Thymidine metabolism
  • Thymidine pharmacokinetics
  • Thymidine toxicity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Clinical and biochemical studies of high-dose thymidine treatment in patients with solid tumors'. Together they form a unique fingerprint.

Cite this